Overview Press Releases Events and Presentations Financials and Filings Stock Information Corporate Governance FAQs Madrigal press releases are available below. Search them by keyword or browse by date. Year None2022202120202019201820172016 May 17, 2022 Madrigal Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences May 9, 2022 Madrigal Pharmaceuticals Provides Clinical and Business Updates and Reports 2022 First Quarter Financial Results April 28, 2022 Madrigal Pharmaceuticals to Announce First Quarter 2022 Financial Results and Provide Clinical and Business Updates on May 9 March 9, 2022 Madrigal Pharmaceuticals to Present at the Oppenheimer Healthcare Conference February 24, 2022 Madrigal Pharmaceuticals Provides Business and Clinical Updates and Reports 2021 Fourth Quarter and Full Year Financial Results January 31, 2022 Positive Topline Phase 3 MAESTRO-NAFLD-1 Data Demonstrate Resmetirom was Safe, Well-Tolerated and Provided Statistically Significant Improvements in Key Measures of Liver and Cardiovascular Health January 30, 2022 Madrigal Pharmaceuticals To Announce Topline Results from the Phase 3 MAESTRO-NAFLD-1 Study of Resmetirom on Monday, January 31st January 10, 2022 Dominic F. Labriola Joins Madrigal Pharmaceuticals as Chief Data and Analytics Officer
Madrigal press releases are available below. Search them by keyword or browse by date. Year None2022202120202019201820172016 May 17, 2022 Madrigal Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences May 9, 2022 Madrigal Pharmaceuticals Provides Clinical and Business Updates and Reports 2022 First Quarter Financial Results April 28, 2022 Madrigal Pharmaceuticals to Announce First Quarter 2022 Financial Results and Provide Clinical and Business Updates on May 9 March 9, 2022 Madrigal Pharmaceuticals to Present at the Oppenheimer Healthcare Conference February 24, 2022 Madrigal Pharmaceuticals Provides Business and Clinical Updates and Reports 2021 Fourth Quarter and Full Year Financial Results January 31, 2022 Positive Topline Phase 3 MAESTRO-NAFLD-1 Data Demonstrate Resmetirom was Safe, Well-Tolerated and Provided Statistically Significant Improvements in Key Measures of Liver and Cardiovascular Health January 30, 2022 Madrigal Pharmaceuticals To Announce Topline Results from the Phase 3 MAESTRO-NAFLD-1 Study of Resmetirom on Monday, January 31st January 10, 2022 Dominic F. Labriola Joins Madrigal Pharmaceuticals as Chief Data and Analytics Officer
May 9, 2022 Madrigal Pharmaceuticals Provides Clinical and Business Updates and Reports 2022 First Quarter Financial Results
April 28, 2022 Madrigal Pharmaceuticals to Announce First Quarter 2022 Financial Results and Provide Clinical and Business Updates on May 9
February 24, 2022 Madrigal Pharmaceuticals Provides Business and Clinical Updates and Reports 2021 Fourth Quarter and Full Year Financial Results
January 31, 2022 Positive Topline Phase 3 MAESTRO-NAFLD-1 Data Demonstrate Resmetirom was Safe, Well-Tolerated and Provided Statistically Significant Improvements in Key Measures of Liver and Cardiovascular Health
January 30, 2022 Madrigal Pharmaceuticals To Announce Topline Results from the Phase 3 MAESTRO-NAFLD-1 Study of Resmetirom on Monday, January 31st
January 10, 2022 Dominic F. Labriola Joins Madrigal Pharmaceuticals as Chief Data and Analytics Officer
